Proteasome inhibitor

Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Dexamethasone, ASH, CRS, Patient, Cell, Infection, Bortezomib, B-cell maturation antigen, GPRC5D, Carfilzomib, Therapy, Bristol Myers Squibb, ORR, Cancer, Diagnosis, Anemia, International Myeloma Foundation, CD3, Cytokine release syndrome, Haematopoietic system, Multiple myeloma, Immunomodulatory imide drug, Safety, Immune system, Incidence, Aes, DOR, Science, Hook effect, Public, Drug discovery, Society, Estate (law), Lenalidomide, Proteasome inhibitor, Thrombocytopenia, PFS, BMY, Daratumumab, Neutropenia, Partnership, Skin, Life, Mezi proudy, Research, NYSE, Disease, MRD, Translational Genomics Research Institute, TCE, Survival, BMS, BCMA, Biology, Pharmaceutical industry, Vaccine, Fine chemical, Cohort, RRMM

Bristol Myers Squibb (NYSE: BMY) today announced updated results from three key programs within its broad multiple myeloma research pipeline, highlighting its diverse targets and molecular approaches to address unique patient needs within the disease.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced updated results from three key programs within its broad multiple myeloma research pipeline, highlighting its diverse targets and molecular approaches to address unique patient needs within the disease.
  • These data were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California.
  • While multiple myeloma remains a relentless disease, we continue to transform the multiple myeloma treatment paradigm by dramatically improving outcomes for every patient.
  • As a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.

Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Retrieved on: 
Wednesday, December 6, 2023
NDA, Dexamethasone, Immunotherapy, NCCN, Disease, Hematology, Proteasome inhibitor, ESMO, Diagnosis, Multiple myeloma, International Myeloma Foundation, Patient, Guideline, Chinese, XPO1, Therapy, Selinexor, Oncology, Growth, CSCO, Pi, HIV disease progression rates, Pharmaceutical industry, Medical device

XPOVIO® has received regulatory approvals in 42 countries and regions including Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia.

Key Points: 
  • XPOVIO® has received regulatory approvals in 42 countries and regions including Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia.
  • XPOVIO® is the world's first oral selective inhibitor of the nuclear export protein XPO1, with regulatory approvals in 42 countries and regions including Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia.
  • "Antengene is excited to receive approval of XPOVIO® in Macau, first in the next wave of expected approvals in the APAC."
  • I am glad that XPOVIO® has become the first and only XPO1 inhibitor approved for the treatment of patients with R/R MM in Macau China.

Cellectar Biosciences Highlights Promising Interim Data from Its Ongoing Study of Iopofosine I 131 in Multiple Myeloma in an Oral Presentation at the SNMMI Annual Meeting

Retrieved on: 
Wednesday, June 28, 2023
Neutropenia, Society, Bleeding, SNMMI, Civil service commission, ODD, Multiple myeloma, Primary central nervous system lymphoma, Molecular imaging, DCR, Diabetic neuropathy, Cancer, CBR, PFS, MCI, Radiation, Hematological Cancer Research Investment and Education Act, TAD, Macroglobulinemia, European Commission, MD, Patient, Anemia, Cytopenia, Annual general meeting, MM, Arrhythmia, Poster, FDA, Proteasome inhibitor, Thrombocytopenia, ORR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, BCMA, Pharmaceutical industry, Tissue paper, Mineral wool

FLORHAM PARK, N.J., June 28, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced it presented data at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting from 64 evaluable, relapsed, or refractory multiple myeloma (MM) patients in which iopofosine I 131 demonstrated an overall response rate (ORR) of 28%, a clinical benefit rate (CBR) of 70% and a disease control rate (DCR) of 92%.

Key Points: 
  • “Our first-in-class targeted radiotherapy, iopofosine I 131, continues to deliver impressive results in patients with hematologic cancers.
  • Currently, there is a significant unmet need for patients with refractory multiple myeloma, who essentially have no treatment options once previous therapies stop working,” said Andrei Shustov, MD, senior vice president, medical.
  • The oral presentation highlighted data demonstrating the outcomes from two dose levels (60 mCi total administered dose) across these highly refractory patients.
  • A copy of the poster is available on the Posters and Publications section of the company’s website.

IASO Bio and Innovent Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel（BCMA CAR-T Cell Therapy）for Multiple Myeloma at the 2023 ASCO Annual Meeting

Retrieved on: 
Monday, June 5, 2023
Tongji Hospital station, DNA, Fragment crystallizable region, Pi, Biotechnology, SCR, CRS, Hook effect, DOR, B-cell maturation antigen, American Society of Clinical Oncology, Bone marrow, Huachung University, Cmax, Doctor of Philosophy, PFS, Trial of the century, MTTR, ASCO, MRD, CAR, Tongji Medical College, CR, Congress, Multiple myeloma, MD, Patient, Cytokine release syndrome, SAN, EMM, Annual general meeting, Immunotherapy, EHA, MM, RRMM, Huazhong University of Science and Technology, Proteasome inhibitor, Society, ADA, ORR, BCMA, Safety, Center for Innovative Phage Applications and Therapeutics, Disease, Vaccine, Pharmaceutical industry

The updated data showed long-term follow-up efficacy and safety of the phase 1b/2 study (FUMANBA-1) conducted in 14 centers in China.

Key Points: 
  • The updated data showed long-term follow-up efficacy and safety of the phase 1b/2 study (FUMANBA-1) conducted in 14 centers in China.
  • Among the 103 patients, 68.9% (71/103) had high-risk cytogenetic abnormalities per mSMART 3.0, 12.6%（13/103）had extramedullary multiple myeloma (EMM), and 11.7%（12/103）had received prior CAR-T therapy.
  • Equecabtagene Autoleucel demonstrated a favorable and manageable safety profile: Among the 103 patients, 93.2% (96/103) experienced cytokine release syndrome (CRS).
  • These results are encouraging and entails an opportunity to advance Equecabtagene Autoleucel to earlier lines of treatment to benefit more MM patients."

Moleculin Announces Presentation of Positive Pharmacokinetics and Tissue-Organ Distribution Data Demonstrating High Antitumor Activity of Annamycin in Preclinical Cancer Models

Retrieved on: 
Tuesday, April 18, 2023
Orange County Convention Center, DOX, AACR, Liver disease, Hepatocellular carcinoma, ANN, Schweizer SGU 1-6, MIA, Survival, Pharmacokinetics, American Association for Cancer Research, Research, Experiment, Hyperrectangle, MD Anderson Cancer Center, Plasma, Death, Animal, American Society for Pharmacology and Experimental Therapeutics, Division, University, Proteasome inhibitor, Doxorubicin, Topoisomerase, Mouse, Liver, HEPA, Anthracycline, Therapy, LC/MS, Virus, HCC, Medical imaging, Pharmaceutical industry

HOUSTON, April 18, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that positive preclinical data regarding the Company's next-generation anthracycline, Annamycin, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, FL. This research was sponsored by the Company.

Key Points: 
  • "Annamycin has continued to demonstrate in preclinical models promising results in hard-to-treat tumors.
  • The high antitumor activity seen preclinically with Annamycin is very encouraging and provides validation for expanded studies to assess activity in different tumor liver metastasis models as well as HCC models," commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin .
  • The antitumor efficacy of L-ANN was studied using HEPA 1-6 hepatocellular carcinoma models (subcutaneous, orthotopic, and experimental liver metastatic models) as well as CT26 colon cancer and MIA PaCa-2 pancreatic cancer liver metastasis models.
  • Unless specifically noted otherwise, references to "Annamycin" refer to the liposome formulated form of the drug.

Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting

Retrieved on: 
Thursday, April 13, 2023
CLL, NRAS, KRAS, MYC, AACR, Molecule, TP53, Chronic lymphocytic leukemia, Menin, ITD, Acute leukemia, American Association for Cancer Research, MEK, Doctor of Philosophy, BTK, Gene expression profiling, MEN1, NOTCH1, AML, BCL2, Patient, DSM-IV codes, Proteasome inhibitor, Cancer, Acute myeloid leukemia, Growth, Leukemia, Therapy, Gene, Disease, Pharmaceutical industry, Vaccine, Biology, FLT3

Biomea’s preclinical posters will be made available at https://biomeafusion.com/publications/ following presentation at the meeting.

Key Points: 
  • Biomea’s preclinical posters will be made available at https://biomeafusion.com/publications/ following presentation at the meeting.
  • Menin is an epigenetic protein that drives oncogenic function through transcriptional regulation directed by its interactions with various protein partners.
  • Additionally, we show benefit of combinatorial approaches of menin and FLT3 covalent inhibitors with MEK and BCL2 blockade.
  • These data provide initial pre-clinical evidence for combining pathway specific inhibitors as a promising therapeutic strategy for further investigation in acute leukemia.

Avacta to Present Pre-Clinical Data on AVA3996 at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Monday, March 27, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Clinical Trials, AACR, Fiona McLaughlin, Orange County Convention Center, Therapeutic index, American Association for Cancer Research, FAP, Neoplasm, Annual general meeting, Fibroblast activation protein, alpha, Peripheral neuropathy, Poster, Toxic encephalopathy, Tumor microenvironment, Proteasome inhibitor, Biology, Disease

The poster describes the data and pre-clinical rationale for the further development and disease positioning of the Company’s second pre|CISION™ candidate, AVA3996, a tumour microenvironment activated proteasome inhibitor.

Key Points: 
  • The poster describes the data and pre-clinical rationale for the further development and disease positioning of the Company’s second pre|CISION™ candidate, AVA3996, a tumour microenvironment activated proteasome inhibitor.
  • AVA3996 utilises Avacta’s pre|CISION™ platform to improve the therapeutic index and therefore utility of proteasome inhibitors in tumours with high FAP levels, including both solid and haematological tumours.
  • AVA3996 has the potential to deliver efficacious levels of the proteasome inhibitor warhead directly to the tumour microenvironment while reducing systemic exposure and hence associated toxicities, such as peripheral neuropathy.
  • Attending the conference from Avacta will be Fiona McLaughlin – Chief Scientific Officer, Neil Bell – Chief Development Officer, David Jones – VP Biology and Francis Wilson – VP Chemistry.

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on: 
Tuesday, March 21, 2023
Orange County Convention Center, American Association for Cancer Research, AACR, Virus, Proteasome inhibitor, Pharmaceutical industry

HOUSTON, March 21, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that an abstract regarding the Company's next-generation anthracycline, Annamycin , has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, FL.

Key Points: 
  • HOUSTON, March 21, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that an abstract regarding the Company's next-generation anthracycline, Annamycin , has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, FL.
  • Details of the presentation are as follows:
    Session: PO.ET09.10 - Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases

Multiple Myeloma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 16, 2023
Pharmaceutical, Health, Oncology, Population Health Management, PBF, Patient, POLI, Clinical trial, Epidemiology, Multiple myeloma, WMH, Price intelligence, Proteasome inhibitor, Pharmaceutical industry, Fine chemical

The "Multiple Myeloma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Multiple Myeloma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • In addition to PBF sales data for the 8MM, this report contains sales forecast extrapolations for an additional seven geographical markets (7M), totaling 15 markets (15M).
  • Additionally, the report evaluates indication-specific unmet needs, competitive assessment, and identifies key future players in the cell therapy market.
  • The presence of marketed and pipeline CAR-T cell therapies in the 3L+ setting addresses the unmet need of providing therapeutic options for heavily pre-treated patients

U.S. FDA Approves Clinical Trial Application for IASO Bio's BCMA CAR-T CT103A for Relapsed/Refractory Multiple Myeloma

Retrieved on: 
Thursday, December 22, 2022
CD19, Alkylation, EHA, NMOSD, Neuromyelitis optica spectrum disorder, Multiple myeloma, Patient, Proteasome inhibitor, Maxwell, SAN, Food, European Hematology Association, CR, CAR, CRS, Bone marrow, Bone, MTTR, Degenerative disease, BTD, ORR, Anemia, Fragment crystallizable region, Breakthrough therapy, National Medical Products Administration, New Drug Application, Conference, FDA, Safety, Kidney failure, CD8A, Multimedia, Investigational New Drug, ODD, IND, MM, NMPA, NDA, Cytokine release syndrome, B-cell maturation antigen, MRD, BCMA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Drug discovery

Multiple myeloma is a deadly blood cancer that often infiltrates the bone marrow causing anemia, kidney failure, immune problems, and bone fractures.

Key Points: 
  • Multiple myeloma is a deadly blood cancer that often infiltrates the bone marrow causing anemia, kidney failure, immune problems, and bone fractures.
  • In February 2022, CT103A was granted the "orphan drug designation (ODD)" by the FDA for the treatment of multiple myeloma.
  • In June 2022, CT103A was accepted by the NMPA for the NDA application for the treatment of relapsed/refractory multiple myeloma and included in the priority review.
  • The NMPA accepted the New Drug Application for equecabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma (R/R MM).